Quantitative Evaluation of Aldo–keto Reductase Expression in Hepatocellular Carcinoma (HCC) Cell Lines

[1]  B. Wermuth,et al.  The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. , 1989, The Journal of biological chemistry.

[2]  A. Otto,et al.  Identification of tumor-associated protein variants during rat hepatocarcinogenesis. Aldose reductase. , 1994, The Journal of biological chemistry.

[3]  N. Taniguchi,et al.  Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: Implication in detoxification of cytotoxic aldehydes , 1995, International journal of cancer.

[4]  M. Lewis,et al.  Comparative anatomy of the aldo-keto reductase superfamily. , 1997, The Biochemical journal.

[5]  Sheung Tat Fan,et al.  Identification and Characterization of a Novel Human Aldose Reductase-like Gene* , 1998, The Journal of Biological Chemistry.

[6]  G. FitzGerald,et al.  Molecular Evolution of the Aldo-keto Reductase Gene Superfamily , 1998, Journal of Molecular Evolution.

[7]  J. Groopman,et al.  cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. , 1999, Carcinogenesis.

[8]  Michael E. Burczynski,et al.  Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones , 2000 .

[9]  N. Palackal,et al.  Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. , 2000, The Biochemical journal.

[10]  Mark A. Knepper,et al.  Aldose Reductase-Deficient Mice Develop Nephrogenic Diabetes Insipidus , 2000, Molecular and Cellular Biology.

[11]  M. Young,et al.  Functional genomic studies of aldo-keto reductases. , 2001, Chemico-biological interactions.

[12]  J. Jez,et al.  The aldo-keto reductase (AKR) superfamily: an update. , 2001, Chemico-biological interactions.

[13]  Tzei-Yi Lin,et al.  Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. , 2001, Cancer research.

[14]  N. Palackal,et al.  Activation of Polycyclic Aromatic Hydrocarbontrans-Dihydrodiol Proximate Carcinogens by Human Aldo-keto Reductase (AKR1C) Enzymes and Their Functional Overexpression in Human Lung Carcinoma (A549) Cells* , 2002, The Journal of Biological Chemistry.

[15]  Laurent Vergnes,et al.  A cluster of eight hydroxysteroid dehydrogenase genes belonging to the aldo-keto reductase supergene family on mouse chromosome 13 Published, JLR Papers in Press, December 1, 2002. DOI 10.1194/jlr.M200399-JLR200 , 2003, Journal of Lipid Research.

[16]  Trevor M. Penning,et al.  Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate , 2004, Steroids.

[17]  F. Stanczyk,et al.  Selective Loss of AKR1C1 and AKR1C2 in Breast Cancer and Their Potential Effect on Progesterone Signaling , 2004, Cancer Research.

[18]  Wendy J Mack,et al.  Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study , 2005, Breast Cancer Research.

[19]  T. Penning,et al.  Structure–function of human 3α-hydroxysteroid dehydrogenases: genes and proteins , 2004, Molecular and Cellular Endocrinology.

[20]  Liang-Shun Wang,et al.  Inverse expression of dihydrodiol dehydrogenase and glutathione‐S‐transferase in patients with esophageal squamous cell carcinoma , 2004, International journal of cancer.

[21]  T. Penning,et al.  Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. , 2004, Molecular and cellular endocrinology.

[22]  Trevor M Penning,et al.  The roles of aldo-keto reductases in steroid hormone action. , 2004, Drug news & perspectives.

[23]  Trevor M Penning,et al.  AKR1B10: A New Diagnostic Marker of Non–Small Cell Lung Carcinoma in Smokers , 2005, Clinical Cancer Research.

[24]  Hiroyuki Aburatani,et al.  Overexpression of the Aldo-Keto Reductase Family Protein AKR1B10 Is Highly Correlated with Smokers' Non–Small Cell Lung Carcinomas , 2005, Clinical Cancer Research.

[25]  Donna M. Peehl,et al.  Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors , 2006, Molecular and Cellular Endocrinology.

[26]  Peter Boyle,et al.  Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma , 2007, Human Genetics.

[27]  Tea Lanišnik Rižner,et al.  AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer , 2006, Molecular and Cellular Endocrinology.

[28]  Nadarajah Vigneswaran,et al.  Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. , 2006, Toxicology letters.

[29]  M. Srinivasulu,et al.  Overexpression of aldose reductase in human cancer tissues. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[30]  Hsueh-Kung Lin,et al.  Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. , 2006, Endocrine-related cancer.

[31]  Ming-Chih Chou,et al.  Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer. , 2007, Oncology reports.

[32]  Yi Jin,et al.  Aldo-keto reductases and bioactivation/detoxication. , 2007, Annual review of pharmacology and toxicology.

[33]  Rong Wang,et al.  Comparative analysis of the protein profiles from primary gastric tumors and their adjacent regions: MAWBP could be a new protein candidate involved in gastric cancer. , 2007, Journal of proteome research.

[34]  Trevor M Penning,et al.  Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. , 2007, Archives of biochemistry and biophysics.

[35]  Debra Silverman,et al.  Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. , 2008, Carcinogenesis.

[36]  Trevor M Penning,et al.  Comparisons of (+/-)-benzo[a]pyrene-trans-7,8-dihydrodiol activation by human cytochrome P450 and aldo-keto reductase enzymes: effect of redox state and expression levels. , 2008, Chemical research in toxicology.

[37]  Hiroyuki Aburatani,et al.  AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. , 2008, Pathology, research and practice.

[38]  Kun-Tu Yeh,et al.  Overexpression of Dihydrodiol Dehydrogenase as a Prognostic Marker in Resected Gastric Cancer Patients , 2009, Digestive Diseases and Sciences.

[39]  J Mark Petrash,et al.  Disruption of aldo-keto reductase genes leads to elevated markers of oxidative stress and inositol auxotrophy in Saccharomyces cerevisiae. , 2008, Biochimica et biophysica acta.

[40]  Wei Tong,et al.  A new approach to monitor expression of aldo–keto reductase proteins in mouse tissues , 2009, Proteomics.

[41]  Trevor M Penning,et al.  Steroid Hormone Transforming Aldo‐Keto Reductases and Cancer , 2009, Annals of the New York Academy of Sciences.

[42]  I-Ping Chiang,et al.  Overexpression of aldo‐keto reductase 1C2 is associated with disease progression in patients with prostatic cancer , 2010, Histopathology.

[43]  Fiona Campbell,et al.  Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy , 2011, Molecular Cancer.

[44]  Kota V Ramana,et al.  Aldose reductase inhibition: emerging drug target for the treatment of cardiovascular complications. , 2010, Recent patents on cardiovascular drug discovery.

[45]  Hyun-Ho Lim,et al.  High-Efficiency Screening of Monoclonal Antibodies for Membrane Protein Crystallography , 2011, PloS one.

[46]  E-S Lee,et al.  AKR1B10 is Associated with Smoking and Smoking-Related Non-Small-Cell Lung Cancer , 2011, The Journal of international medical research.

[47]  György Marko-Varga,et al.  Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study , 2011, Journal of Clinical Bioinformatics.

[48]  J. Farrés,et al.  Biological Role of Aldo–Keto Reductases in Retinoic Acid Biosynthesis and Signaling , 2012, Front. Pharmacol..

[49]  J. M. Petrash,et al.  Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers , 2012, Front. Pharmacol..

[50]  Bruce E Johnson,et al.  The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  L. Wong,et al.  Proteomics Signature Profiling (PSP): A Novel Contextualization Approach for Cancer Proteomics , 2012, Journal of proteome research.

[52]  Valerie L. Miller,et al.  Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. , 2012, International journal of clinical and experimental pathology.

[53]  Ashish Saxena,et al.  Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a. , 2013, Antioxidants & redox signaling.